Recent Updates
Recently added Catalysts
SLN Positive Sentiment

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Silence Therapeutics announced that data from its SANRECO Phase 2 study of divesiran has been accepted for oral presentation at the ASH Annual Meeting in December 2026. Divesiran targets TMPRSS6 and is designed for treating polycythemia vera. This presentation highlights the company's ongoing commitment to innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Data accepted for oral presentation at ASH 2026.
  • Divesiran is a first-in-class siRNA therapy.
  • Focus on polycythemia vera, a significant medical need.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
5%
average across 6 past catalysts
Lead asset
SLN124
Phase 2 · Polycythemia Vera

Full Press Release Details

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA. Presentation Details: Presenting Author:

Frequently Asked Questions

What is the SANRECO study about?

The SANRECO study focuses on the Phase 2 evaluation of divesiran in polycythemia vera.

When will the ASH Annual Meeting take place?

The ASH Annual Meeting will be held from December 12-15, 2026.

What is divesiran targeting?

Divesiran is designed to silence TMPRSS6 in patients with polycythemia vera.

Who is presenting the data at ASH?

The presenting author has not been specified in the announcement.

ShareAdd on Google
Tags: SLN Silence Therapeutics Divesiran Polycythemia Vera ASH 2026 siRNA
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$72M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SLN124Phase 2
Polycythemia Vera →

Catalyst track record

+181%
best trade around SLN's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SLN.

See every catalyst's timing & PoA →